Woher kommt der grüne Wasserstoff?

Grüner Wasserstoff ist eine Voraussetzung zur Errei- chung von Klimaneutralität. Die Potenziale zur grü- nen Wasserstoffproduktion sind weltweit verteilt. Die technologische Weiterentwicklung in den Bereichen erneuerbare Energieerzeugung und Elektrolyse wird dazu führen, dass die Gestehungskosten für grünen Wasserstoff sich weltweit angleichen und andere Standortfaktoren stärker in den Vordergrund rücken. Dazu gehören die Verfügbarkeit von Flächen zur EE- Produktion und die Investitionssicherheit durch stabile politische Rahmenbedingungen. Auch Nach- haltigkeitskriterien z. B. bei der Wasserbereitstellung müssen berücksichtigt werden. Da schon bald grö- ßere Mengen an grünem Wasserstoff benötigt wer- den, sollten die weltweit vorhandenen nachhaltig nutzbaren Potenziale in internationaler Partnerschaft parallel ausgebaut werden. Grüner Wasserstoff wird zum globalen Handeslgu

Woher kommt der grüne Wasserstoff?

Das Energiesystem der Zukunft wird stark durch Elektrifizierung geprägt sein. Für die Langzeitspeicherung von Energie sowie für Bereiche, die sich nicht sinnvoll durch Strom defossilieren lassen, werden aber auch in Zukunft chemische Energieträger benötigt. Das Ziel der Klimaneutralität bedingt, dass diese Energieträger vollständig emissionsfrei aus erneuerbaren Energien (EE) hergestellt werden. Diese grünen Energieträger sind transportier- und handelbar, sodass sich ein internationaler Markt für grünen Wasserstoff und seine Folgeprodukte entwickeln wird. Derzeit gibt es diesen Markt noch nicht. Grüner Wasserstoff ist preislich noch nicht konkurrenzfähig gegenüber fossilen Brennstoffen. Den größten Anteil am Wasserstoffpreis haben die Kosten für die Elektrolyseanlage sowie die Kosten für die Strombereitstellung. Die besten Bedingungen für die Wasserstoffproduktion bieten daher EE-Standorte und Technologien mit hohen Volllaststundenzahlen, an denen auch der Elektrolyseur bei wenig EE-Abregelung auf viele Betriebsstunden kommt

Altered energy partitioning across terrestrial ecosystems in the European drought year 2018

Drought and heat events, such as the 2018 European drought, interact with the exchange of energy between the land surface and the atmosphere, potentially affecting albedo, sensible and latent heat fluxes, as well as CO(2)exchange. Each of these quantities may aggravate or mitigate the drought, heat, their side effects on productivity, water scarcity and global warming. We used measurements of 56 eddy covariance sites across Europe to examine the response of fluxes to extreme drought prevailing most of the year 2018 and how the response differed across various ecosystem types (forests, grasslands, croplands and peatlands). Each component of the surface radiation and energy balance observed in 2018 was compared to available data per site during a reference period 2004-2017. Based on anomalies in precipitation and reference evapotranspiration, we classified 46 sites as drought affected. These received on average 9% more solar radiation and released 32% more sensible heat to the atmosphere compared to the mean of the reference period. In general, drought decreased net CO(2)uptake by 17.8%, but did not significantly change net evapotranspiration. The response of these fluxes differed characteristically between ecosystems; in particular, the general increase in the evaporative index was strongest in peatlands and weakest in croplands. This article is part of the theme issue 'Impacts of the 2018 severe drought and heatwave in Europe: from site to continental scale'

Differential Postprandial Lipoprotein Responses in Type 2 Diabetic Men with and without Clinical Evidence of a Former Myocardial Infarction

Postprandial lipemia plays an important role in the development of coronary heart disease through an elevation of triglyceride-rich lipoproteins. In type 2 diabetic male subjects, our aim was to compare postprandial lipemia in a high-risk population with former myocardial infarction (MI) with that of a lower risk population free of clinically detectable heart disease. 32 male type 2 diabetic subjects were included in the study. We matched 17 cases with a verified history of MI with 15 controls according to age, BMI, HbA1c, diabetes duration, smoking, and treatment of diabetes. Ongoing metformin, insulin, or lipid lowering pharmacological treatment were exclusion criteria. After a maximal exercise tolerance test and echocardiography, the subjects underwent a hyperinsulinemic, euglycemic clamp and a vitamin A fat loading test. Plasma triglyceride levels in the case group were significantly higher after 360 minutes (4.6 ± 3.1 vs. 2.8 ± 1.8 mmol/l, p = 0.04) and 480 minutes (3.6 ± 2.2 vs. 2.4 ± 2.4 mmol/l, p = 0.03), as was the incremental Area Under the Curve (iAUC) for the whole period (560 ± 452 vs. 297 ± 214 mmolx480min./l; p = 0.048). In addition, the retinyl palmitate responses in the chylomicron-fraction from the case group were significantly higher (iAUC 311,502 ± 194,933 vs. 187,004 ± 102,928 ngx480min./ml; p = 0.035). Type 2 diabetic males with prior MI had higher postprandial triglyceride-rich lipoprotein responses than those without MI, indicating that high responses may be a marker for a high-risk population

Auf dem Weg in eine nachhaltige Wasserstoffwirtschaft

Der Klimawandel stellt uns vor die globale Herausforderung, auf fossile Energieträger zu verzichten. Die erfolgreiche Transformation des Energiesystems ist eine wesentliche Voraussetzung für eine vollständige Reduktion der Treibhausgase. Eine solche Transformation kann nur gelingen, wenn der fundamental neue Charakter des Systems erfasst und im abgeleiteten Rückschluss daraus der passende Pfad eingeschlagen wird. Im Kern lässt sich dieser neue Charakter als ein defossilisiertes, auf regenerativen Energien basierendes Energiesystem beschreiben

Gastrointestinal hormones and β-cell function after gastric bypass and sleeve gastrectomy: an RCT (Oseberg)

Context Whether Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differentially affect postprandial gastrointestinal hormones and β-cell function in type 2 diabetes remains unclear. Objective To compare gastrointestinal hormones and β-cell function assessed by an oral glucose tolerance test (OGTT) 5 weeks and 1 year after surgery hypothesizing higher GLP-1 levels and greater β-cell response to glucose after RYGB than after SG. Design, Setting, Patients, and Interventions Randomized, triple blind, single-center trial at a tertiary care center in Norway. Primary outcomes; diabetes remission and IVGTT derived β-cell function. Participants with obesity and type 2 diabetes allocated (1:1) to RYGB or SG. Main outcome measures Gastrointestinal hormone profiles and insulin secretion [β-cell glucose sensitivity (β-GS)] derived from 180 minutes OGTTs. Results 106 patients (67% women), mean (SD) age 48 (10) years. Diabetes remission rates at 1-year were higher after RYGB than after SG, 77% versus 48%, p = 0.002. Incremental area under the curve (iAUC0-180) glucagon-like peptide-1 (GLP-1) and β-GS increased more after RYGB than after SG, 1-year between-group difference 1173 pmol/l*min (95% CI 569 to 1776), p = 0.0010, and 0.45 pmol/kg/min/mmol (95% CI 0.15 to 0.75), p = 0.0032, respectively. Post-surgery, fasting and postprandial ghrelin levels were higher and decremental AUC0-180 ghrelin, iAUC0-180 glucose-dependent insulinotropic polypeptide, and iAUC0-60 glucagon were greater after RYGB than after SG. Diabetes remission at 1 year was associated with higher β-GS and higher GLP-1 secretion. Conclusions RYGB was associated with greater improvement in β-cell function and higher postprandial GLP-1 levels than SG

Gastrointestinal hormones and β-cell function after gastric bypass and sleeve gastrectomy: an RCT (Oseberg)

Context Whether Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differentially affect postprandial gastrointestinal hormones and β-cell function in type 2 diabetes remains unclear. Objective To compare gastrointestinal hormones and β-cell function assessed by an oral glucose tolerance test (OGTT) 5 weeks and 1 year after surgery hypothesizing higher GLP-1 levels and greater β-cell response to glucose after RYGB than after SG. Design, Setting, Patients, and Interventions Randomized, triple blind, single-center trial at a tertiary care center in Norway. Primary outcomes; diabetes remission and IVGTT derived β-cell function. Participants with obesity and type 2 diabetes allocated (1:1) to RYGB or SG. Main outcome measures Gastrointestinal hormone profiles and insulin secretion [β-cell glucose sensitivity (β-GS)] derived from 180 minutes OGTTs. Results 106 patients (67% women), mean (SD) age 48 (10) years. Diabetes remission rates at 1-year were higher after RYGB than after SG, 77% versus 48%, p = 0.002. Incremental area under the curve (iAUC0-180) glucagon-like peptide-1 (GLP-1) and β-GS increased more after RYGB than after SG, 1-year between-group difference 1173 pmol/l*min (95% CI 569 to 1776), p = 0.0010, and 0.45 pmol/kg/min/mmol (95% CI 0.15 to 0.75), p = 0.0032, respectively. Post-surgery, fasting and postprandial ghrelin levels were higher and decremental AUC0-180 ghrelin, iAUC0-180 glucose-dependent insulinotropic polypeptide, and iAUC0-60 glucagon were greater after RYGB than after SG. Diabetes remission at 1 year was associated with higher β-GS and higher GLP-1 secretion. Conclusions RYGB was associated with greater improvement in β-cell function and higher postprandial GLP-1 levels than SG

Export Potentials of Green Hydrogen - Methodology for a Techno-Economic Assessment. Annex A.1 - Modeling parameters

This working paper describes the quantitative and model-based methodology used in HYPAT to assess hydrogen and Power-to-X (PtX) export potentials in the countries Morocco, Ukraine, Namibia, Turkey, United Arab Emirates, Kenya, Chile, Canada, Brazil, and New Zealand. The results of the techno-economic assessment are further used as a basis for a global hydrogen and PtX atlas, and as an indication of the price development of hydrogen and PtX

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

© 2019, The Author(s). Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. Objective: The aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD. Methods: This analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates. Results: Of 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections were reduced with dupilumab (risk ratio 0.43; p \u3c 0.05), as were bacterial and other non-herpetic skin infections (risk ratio 0.44; p \u3c 0.001). Although herpesviral infection rates overall were slightly higher with dupilumab than placebo, clinically important herpesviral infections (eczema herpeticum, herpes zoster) were less common with dupilumab (risk ratio 0.31; p \u3c 0.01). Systemic anti-infective medication use was lower with dupilumab. Conclusions: Dupilumab is associated with reduced risk of serious/severe infections and non-herpetic skin infections and does not increase overall infection rates versus placebo in patients with moderate-to-severe AD. ClinicalTrials.gov Identifiers: NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649